£2.1M
The financing round will help the medical technology company advance its epilepsy diagnosis software towards US and Middle Eastern markets.
N
Neuronostics
Neuronostics develops digital biomarkers and software to improve the diagnosis of neurological conditions.
£2.4MTotal raised
Neuronostics is a medical technology start-up that develops mathematical and computational tools to improve the diagnosis and treatment of neurological conditions. Based in the UK, the company creates digital biomarkers like BioEP to enhance standard clinical recordings.
Filed accounts
Shareholders' funds
Members only
Turnover
Members only
Profit for the year
Members only
Employees
Members only
Cash, assets and headcount from Neuronostics's latest Companies House filing — with year-on-year movement, free with a Winfred account.
Categories
Founders
John Terry
Co-Founder
John brings academic and founding experience, serving as Managing Director of Neuronostics and Professor of Digital Health Innovation at the University of Plymouth. He previously held research and professorial roles at the Universities of Birmingham and Exeter.
LinkedIn
Wessel Woldman
Co-Founder
Wessel is the co-founder and scientific director of Neuronostics. He brings academic research experience from the University of Birmingham and the University of Exeter.
LinkedInInvestors
- £2.1M
- £300KQantXLead
Funding history
£300K
The seed round was backed by private investors establishing QantX Ventures to fund clinical development.